Personalised Medicine Readiness Assessment

Our “Personalised Medicine Readiness Assessment” reviews both the suitability of a portfolio and the degree of penetration of Personalised Medicine into established R&D processes as well as the technological infrastructure ultimately required to develop an actionable strategy.

The “Personalised Medicine Readiness Assessment” has been developed to help companies quickly establish a competitive position and strategy in the field of personalised medicine by answering a few essential questions in three steps:

Step one contains a thorough review of a company’s current position in the Personalised Medicine space:

  • Is there an overall strategic intent with respect to Personalised Medicine beyond R&D?
  • What is the potential impact of Personalised Medicine on company’s portfolio – based on indications and selected individual projects?
  • To what extent have processes and checkpoints for biomarkers been established?
  • What internal capabilities for biomarkers have been established?
  • What types of partnering activities have been started in Personalised Medicine?

In a second step we define the optimal position of a company in the Personalised Medicine space and define the activities required to close the gaps:

  • What strategy would be optimal with a given impact of Personalised Medicine on company’s portfolio?
  • What are the lessons learnt and best practices from other companies in similar positions?
  • What role should Personalised Medicine play in company strategy?
  • What are the required internal capabilities?
    • Skills and technologies
    • Processes and organisation
    • Partnering strategy
  • Which development projects would benefit most from a biomarker strategy?

In a last step we assess the feasibility of Personalised Medicine concepts at the portfolio level and define concrete action plans for individual projects:

  • How attractive is the Personalised Medicine value proposition for a particular project (NPV with and without Personalised Medicine)?
  • Is a Personalised Medicine strategy technically feasible based on sample availability, marker statistics, diagnostics platform, etc.?
  • What would a commercialisation concept look like (timelines, costs, partnering requirements, distribution strategy, pricing, etc.)?

In addition, we have developed specific project evaluation tools to review any R&D project with and without biomarkers based on an in–depth assessment of the statistical and commercial requirements. Our R&D Risk Assessment contains many criteria assessing the risk profile associated with biomarkers.